“The commercial availability of this new offering is a testament to our decade-long partnership with Dexcom and shared commitment to continued leadership in advancing AID systems,” said Mark Novara, ...

SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company today announced the Tandem t:slim X2™ insulin pump with Control-IQ+ ...

Tandem Diabetes Care, Insulet and Dexcom all presented data over the weekend at the American Diabetes Association’s ...

SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (TNDM), a leading insulin delivery and diabetes technology company, today announced Health Canada authorization for distribution of the Tandem t ...

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) has announced a voluntary medical device correction for select t:slim X2 insulin pumps to ...

Tandem Diabetes Care has sent an “Urgent Medical Device Correction” letter to potentially affected users of the t:slim X2 insulin pump, cautioning that the pump’s speaker could fail, causing insulin ...

Tandem announced Thursday morning that it had won an important approval from the European Union's (EU) European Medicines Agency (EMA). The green light was turned on for the company's t:slim X2 ...

The US Food and Drug Administration (FDA) has expanded the indication for Tandem Diabetes Care’s Control-IQ+ Technology to include people with type 2 diabetes (T2D). The next-generation Control-IQ+ ...

MARKHAM, Ontario--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. today announced that following the recent authorization of sale by Health Canada, in-warranty t:slim X2™ ...